Microenvironment and multiple myeloma spread (Q38214953)

31 August 2017

title

Microenvironment and multiple myeloma spread (English)

1 reference

31 August 2017

1 reference

1

Domenico Ribatti

1 reference

31 August 2017

Michele Moschetta

2

1 reference

31 August 2017

Angelo Vacca

series ordinal

3

1 reference

31 August 2017

publication date

1 May 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

133 Suppl 2

1 reference

31 August 2017

page(s)

S102-6

1 reference

Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Bone marrow vascular niche and the control of tumor growth in hematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

The hematopoietic stem cell in its place

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Cytokines and signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

The bone marrow vascular niche: home of HSC differentiation and mobilization

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

The stem cell niches in bone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Stem cell regulatory niches and their role in normal and malignant hematopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Myeloma bone disease: pathophysiology and management.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Endothelial cells in the bone marrow of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Circulating endothelial progenitor cells in multiple myeloma: implications and significance

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Endothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Mast cells contribute to vasculogenic mimicry in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Osteoclasts are important for bone angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Therapeutic renaissance of thalidomide in the treatment of haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Front-line treatment in younger patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Targeting proteasomes as therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

Acquired free protein S deficiency associated with multiple myeloma: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950017-5

7 January 2021

10.1016/S0049-3848(14)50017-5

Identifiers

DOI

1 reference

31 August 2017

1 reference